$10.76 $0.10 per serving
Product analysis
Double Strength Ginkgo Biloba 120 mg combines ginkgo and eleuthero in a compact herb formula. The eleuthero plant part and the proportions of the named ginkgo compounds are not specified, limiting like-for-like comparisons.
AI assessment of the formula, label and price. How scoring works
Nutrient Quality33
The ginkgo compounds are named, but their relative preparation quality remains uncertain. The eleuthero plant part is not identified.
Ingredient Transparency65
Ingredient amounts are disclosed. Incomplete preparation details limit like-for-like comparisons.
Value For Money62
The serving cost is favorable for its eleuthero contribution. Value for the ginkgo contribution remains uncertain.
Customer Satisfaction94
Customer ratings are strongly favorable. A large rating pool provides a broader view of customer satisfaction.
Product Focus58
The ingredient mixture stays relatively small. Its practical contribution across the intended uses remains modest and uncertain.
- Format
Capsule - Container
- 100 Capsule(s)
- Per serving
- $0.10
- Also available
Double Strength Ginkgo Biloba 120 mg$21.84- Customer rating
- 4.8 · 38,566 ratings
Goals
Impact
Moderate effect
Ginkgo at 120 mg provides the main brain-health link through the supplied findings on brain energy processes. Its cognitive benefits remain situation-dependent, with mixed evidence for general adult use.
How this product is rated for Brain Health
Ingredient fit80
The relevant ingredients fit the goal, with the declared amounts and broader formula focus shaping their contribution.
Goal fit
A relevant brain-health ingredient is present, alongside a broader nutritional focus.
Dose adequacy
The assessed ingredient amount reaches the supplied comparison range.
Pathways43
The main assessed contribution is concentrated in brain energy processes.
Depth
The strongest saved finding concerns brain energy processes, with meaningful but limited coverage.
Breadth
The saved findings concentrate on brain energy processes, rather than several well-covered processes.
Evidence58
Ginkgo evidence is mixed and supports only a limited, situation-dependent contribution. The saved assessment recognizes the preparation for the ingredients included in this finding.
Evidence strength
Ginkgo evidence is mixed and supports only a limited, situation-dependent contribution.
Studied preparation
The saved assessment recognizes the preparation for the ingredients included in this finding.
Formulation logic100
The assessed ingredients need no additional partner, and no configured conflicts were found.
Partner coverage
The assessed ingredients can contribute without an additional required partner.
Conflicts
No configured ingredient conflict was identified in the supplied assessment.
Effective doses
The ingredients included in this saved finding meet its amount threshold.
Impact
Moderate effect
Ginkgo at 120 mg provides the main contribution through support for brain circulation. Eleuthero at 250 mg adds a smaller link to mental performance under stress, with both preparations having a limited match to the supplied trial evidence.
How this product is rated for Cognitive Support
Ingredient fit91
The relevant ingredients give the formula a clear connection to cognitive support. The assessed amounts provide substantial support, with some smaller contributions.
Goal fit
The relevant ingredients give the formula a clear connection to cognitive support.
Dose adequacy
The assessed amounts provide substantial support, with some smaller contributions.
Pathways40
The clearest contribution involves cerebral blood flow, with meaningful coverage in the saved findings. One assessed mechanism reaches meaningful coverage, so support remains focused.
Depth
The clearest contribution involves cerebral blood flow, with meaningful coverage in the saved findings.
Breadth
One assessed mechanism reaches meaningful coverage, so support remains focused.
Evidence25
Ginkgo provides the strongest relevant evidence at an assessed amount, although the support is limited to the outcomes and preparations described. The assessed preparations are not matched to the materials used in the supplied trials.
Evidence strength
Ginkgo provides the strongest relevant evidence at an assessed amount, although the support is limited to the outcomes and preparations described.
Studied preparation
The assessed preparations are not matched to the materials used in the supplied trials.
Formulation logic100
The relevant ingredients can contribute independently or have their needed partner present. No configured ingredient conflict was identified in the saved assessment. All ingredients counted in this finding reach a meaningful amount in the saved comparison.
Partner coverage
The relevant ingredients can contribute independently or have their needed partner present.
Conflicts
No configured ingredient conflict was identified in the saved assessment.
Effective doses
All ingredients counted in this finding reach a meaningful amount in the saved comparison.
Impact
Moderate effect
Eleuthero · 250 mgEleuthero · 250 mg
Ginkgo at 120 mg has mixed evidence for attention and memory. Eleuthero at 250 mg has been considered for fatigue and reduced working capacity, but the supplied evidence gives limited support for improved routine productivity.
How this product is rated for Productivity Boost
Ingredient fit86
The saved findings identify 2 relevant ingredients alongside no other active ingredients. The saved amount assessment is moderate; undisclosed individual amounts reduce certainty about the contribution.
Goal fit
The saved findings identify 2 relevant ingredients alongside no other active ingredients.
Dose adequacy
The saved amount assessment is moderate; undisclosed individual amounts reduce certainty about the contribution.
Pathways13
The strongest assessed area is synaptic plasticity and neuroprotection, with limited coverage. 0 of 3 assessed target areas reach the saved coverage threshold.
Depth
The strongest assessed area is synaptic plasticity and neuroprotection, with limited coverage.
Breadth
0 of 3 assessed target areas reach the saved coverage threshold.
Evidence42
Ginkgo is the strongest evidence contributor at an eligible amount in the saved findings; that comparison does not establish improved work output. Some eligible preparations match those accepted as studied; Eleuthero do not.
Evidence strength
Ginkgo is the strongest evidence contributor at an eligible amount in the saved findings; that comparison does not establish improved work output.
Studied preparation
Some eligible preparations match those accepted as studied; Eleuthero do not.
Formulation logic100
The assessed ingredients can contribute alone or have their required partners. No configured ingredient conflicts were identified in the supplied facts. 2 of 2 assessed ingredients meet the saved minimum amount threshold.
Partner coverage
The assessed ingredients can contribute alone or have their required partners.
Conflicts
No configured ingredient conflicts were identified in the supplied facts.
Effective doses
2 of 2 assessed ingredients meet the saved minimum amount threshold.
Eleuthero Not classified
No linked studies yet.
Impact
Moderate effect
Ginkgo extract at 120 mg has a possible attention-related contribution, though everyday concentration findings are mixed. Eleuthero at 250 mg adds a fatigue-related angle, with evidence tied to selected fatigue settings rather than reliable immediate focus.
How this product is rated for Mental Focus
Ingredient fit83
The relevant ingredients keep a clear focus-related emphasis, while the product also has uses beyond attention. Many relevant amounts reach the saved reference levels, while some are lower.
Goal fit
The relevant ingredients keep a clear focus-related emphasis, while the product also has uses beyond attention.
Dose adequacy
Many relevant amounts reach the saved reference levels, while some are lower.
Pathways44
The strongest saved connection is cerebral energy supply, with partial coverage. The saved findings identify 1 sufficiently covered focus mechanism, so support remains concentrated rather than broad.
Depth
The strongest saved connection is cerebral energy supply, with partial coverage.
Breadth
The saved findings identify 1 sufficiently covered focus mechanism, so support remains concentrated rather than broad.
Evidence62
Ginkgo provides the strongest saved evidence among ingredients meeting the amount threshold. Ingredient-specific limitations still matter for everyday focus. The saved preparation check is satisfied for the relevant ingredients at qualifying amounts. That finding does not remove limitations in the attention evidence.
Evidence strength
Ginkgo provides the strongest saved evidence among ingredients meeting the amount threshold. Ingredient-specific limitations still matter for everyday focus.
Studied preparation
The saved preparation check is satisfied for the relevant ingredients at qualifying amounts. That finding does not remove limitations in the attention evidence.
Formulation logic100
The saved findings identify no missing required ingredient partner. No configured ingredient conflict was found in the supplied record.
Partner coverage
The saved findings identify no missing required ingredient partner.
Conflicts
No configured ingredient conflict was found in the supplied record.
Effective doses
All ingredients counted in the saved amount check reach its minimum threshold; that threshold is not a guarantee of noticeable benefit.
Impact
Moderate effect
Whether ginkgo improves everyday vision is unclear. Its connection with blood flow in the eye doesn't mean a generic ginkgo extract will improve contrast or the area you can see. Benefits from specific preparations in people with glaucoma can't be assumed to apply here.
How this product is rated for Eye Health
Ingredient fit60
Ginkgo is declared at 120 mg per serving.
Goal fit
The eye-related ingredients sit alongside other actives whose contribution to everyday vision is unclear.
Dose adequacy
Ginkgo is declared at 120 mg per serving.
Pathways40
The ingredients are mainly connected with blood flow in the eye. That describes their role, rather than a promise of visibly better eyesight.
Depth
The clearest ingredient connection is with blood flow in the eye; this doesn't guarantee a noticeable change in eyesight.
Breadth
The ingredient contribution centers on blood flow in the eye, rather than broad improvements across eye functions.
Evidence64
Ginkgo's practical benefit for routine vision remains uncertain, and specific extracts aren't interchangeable.
Evidence strength
Ginkgo's practical benefit for routine vision remains uncertain, and specific extracts aren't interchangeable.
Studied preparation
The declared ginkgo amount does not make different extracts interchangeable.
Formulation logic100
The individual ingredient roles do not require an additional missing partner, and no particular conflict is identified. Amounts still matter independently of those relationships.
Partner coverage
No missing ingredient partner is identified for the individual ingredient roles.
Conflicts
No particular ingredient conflict is identified.
Effective doses
The relevant declared ingredient amounts reach the lower part of their comparison ranges; that is not a guarantee of benefit.
Ingredients
| Ingredient | Amount per serving | Score |
|---|---|---|
Ginkgo extract (Ginkgoflavonglycosides, Terpene Lactones) | 120 mg | |
organic Eleuthero | 250 mg |
Ginkgo (Ginkgoflavonglycosides, Terpene Lactones) · 120 mg OverallScore71
Each serving lists 120 mg of ginkgo leaf extract. The extract is described as 6% terpenes with a 50:1 extract ratio.
How this ingredient is rated
Composition and Label Disclosure42
The ginkgo extract has a stated 6% terpene content and 50:1 ratio; no flavone percentage is recorded.
Marker and Preparation Disclosure
The extract is listed as 6% terpenes and 50:1; no flavone percentage is recorded in the saved details.
Declared Ginkgolic Acid Limit
No qualifying ginkgolic acid limit is recorded in the saved information, so its level is unknown.
Composition and Label Disclosure100
The selected serving individually lists 120 mg of ginkgo leaf extract.
Individual Preparation Amount Disclosure
The selected serving individually lists 120 mg of ginkgo leaf extract.
Commercial Price and Usability
The whole-product serving costs about $0.11. Price is not evaluated for this ingredient.
Eleuthero · 250 mg OverallScore60
A serving contains 250 mg of eleuthero. The saved facts do not identify the plant part or record an eleutheroside percentage.
How this ingredient is rated
Composition and Label Disclosure0
The plant part is not identified in the saved facts. No eleutheroside percentage, standardization claim or extract ratio is recorded in the saved facts.
Eleutheroside Marker Disclosure
No eleutheroside percentage, standardization claim or extract ratio is recorded in the saved facts.
Target Plant-Part Identification
The plant part is not identified in the saved facts.
Composition and Label Disclosure100
The selected serving lists 250 mg of eleuthero.
Eleuthero Amount Disclosure
The selected serving lists 250 mg of eleuthero.
Commercial Price and Usability100
The whole product costs about $0.11 per serving.
Selected-Serving Price Comparison
The whole product costs about $0.11 per serving.
Alternative products
Report alternatives
Sources
Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.
- Efficacy and adverse effects of ginkgo biloba for cognitive impairment and dementia: a systematic review and meta-analysis.
- Efficacy of Ginkgo biloba extract EGb 761® in dementia with behavioural and psychological symptoms: A systematic review.
- Ginkgo biloba extract EGb 761 is safe and effective in the treatment of mild dementia - a meta-analysis of patient subgroups in randomised controlled trials.
- Ginkgo biloba extract EGb 761® improves cognition and overall condition after ischemic stroke: Results from a pilot randomized trial.
- Ginkgo biloba extract EGb 761® in dementia with neuropsychiatric features: a randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg.
- No benefit adding eleutherococcus senticosus to stress management training in stress-related fatigue/weakness, impaired work or concentration, a randomized controlled study.
- Efficacy of ginkgo diterpene lactone meglumine on cognitive function in patients with acute ischemic stroke: a predefined exploratory analysis of a multicenter, double-blind, randomized controlled trial.
- A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group.
- Alleviating neuropsychiatric symptoms in dementia: the effects of Ginkgo biloba extract EGb 761. Findings from a randomized controlled trial.
- Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: a randomized controlled trial.
- Effect of Ginkgo biloba extracts in the prevention of posterior capsule opacification after cataract surgery: A randomized clinical trial.
- Effect of Ginkgo biloba extract on preexisting visual field damage in normal tension glaucoma.
- [Ginkgo extract in impaired vision--treatment with special extract EGb 761 of impaired vision due to dry senile macular degeneration].
- Short-term effects of Ginkgo biloba extract on peripapillary retinal blood flow in normal tension glaucoma.
- [The course of color vision in early diabetic retinopathy treated with Ginkgo biloba extract. A preliminary double-blind versus placebo study].
- Evidence-based efficacy of adaptogens in fatigue, and molecular mechanisms related to their stress-protective activity.
- Stimulating effect of adaptogens: an overview with particular reference to their efficacy following single dose administration.
- Ginkgo biloba Extract EGb 761 in the Treatment of Patients with Mild Neurocognitive Impairment: A Systematic Review.
- Proof of efficacy of the Ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia.
- Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia.